DK4082530T5 - Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme - Google Patents

Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme Download PDF

Info

Publication number
DK4082530T5
DK4082530T5 DK22162188.1T DK22162188T DK4082530T5 DK 4082530 T5 DK4082530 T5 DK 4082530T5 DK 22162188 T DK22162188 T DK 22162188T DK 4082530 T5 DK4082530 T5 DK 4082530T5
Authority
DK
Denmark
Prior art keywords
same
preparing
methods
compositions
protease inhibitors
Prior art date
Application number
DK22162188.1T
Other languages
English (en)
Other versions
DK4082530T3 (da
Inventor
Avraham Hershko
Miriam Kidron
Original Assignee
Oramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oramed Ltd filed Critical Oramed Ltd
Publication of DK4082530T3 publication Critical patent/DK4082530T3/da
Application granted granted Critical
Publication of DK4082530T5 publication Critical patent/DK4082530T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
DK22162188.1T 2012-02-01 2013-01-31 Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme DK4082530T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261632868P 2012-02-01 2012-02-01
US201261634753P 2012-03-06 2012-03-06
EP13744410.5A EP2814504B1 (en) 2012-02-01 2013-01-31 Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same

Publications (2)

Publication Number Publication Date
DK4082530T3 DK4082530T3 (da) 2024-05-06
DK4082530T5 true DK4082530T5 (da) 2024-07-22

Family

ID=48904507

Family Applications (2)

Application Number Title Priority Date Filing Date
DK22162188.1T DK4082530T5 (da) 2012-02-01 2013-01-31 Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme
DK13744410.5T DK2814504T3 (da) 2012-02-01 2013-01-31 Protease inhibitor indeholdende sammensætninger, sammensætninger omfattende samme og metoder til fremstilling og brug af samme

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK13744410.5T DK2814504T3 (da) 2012-02-01 2013-01-31 Protease inhibitor indeholdende sammensætninger, sammensætninger omfattende samme og metoder til fremstilling og brug af samme

Country Status (9)

Country Link
US (4) US10342764B2 (da)
EP (2) EP4082530B1 (da)
JP (3) JP6567827B2 (da)
CN (3) CN112755002A (da)
DK (2) DK4082530T5 (da)
ES (1) ES2912138T3 (da)
HK (1) HK1200727A1 (da)
HU (1) HUE066433T2 (da)
WO (1) WO2013114369A1 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180228621A1 (en) 2004-08-09 2018-08-16 Mark A. Reiley Apparatus, systems, and methods for the fixation or fusion of bone
AU2006288703B2 (en) * 2005-09-06 2011-09-22 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
CA3083198A1 (en) 2008-03-26 2009-10-01 Oramed Ltd. Methods and compositions for oral administration of proteins
EP2300031B1 (en) 2008-05-05 2017-09-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
ES2644962T3 (es) 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
EP4082530B1 (en) * 2012-02-01 2024-04-10 Oramed Ltd. Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
US10363140B2 (en) 2012-03-09 2019-07-30 Si-Bone Inc. Systems, device, and methods for joint fusion
KR20140147834A (ko) 2012-03-09 2014-12-30 에스아이-본 인코포레이티드 일체형 임플란트
WO2013166496A1 (en) 2012-05-04 2013-11-07 Si-Bone Inc. Fenestrated implant
EP2941267B1 (en) 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
US9936983B2 (en) 2013-03-15 2018-04-10 Si-Bone Inc. Implants for spinal fixation or fusion
US11147688B2 (en) 2013-10-15 2021-10-19 Si-Bone Inc. Implant placement
US10166033B2 (en) 2014-09-18 2019-01-01 Si-Bone Inc. Implants for bone fixation or fusion
US9662157B2 (en) 2014-09-18 2017-05-30 Si-Bone Inc. Matrix implant
CN105343184A (zh) * 2015-12-01 2016-02-24 无限极（中国）有限公司 一种组合物及其应用
EP3429612A4 (en) * 2016-03-16 2020-04-08 AmideBio LLC METHODS OF PRODUCING PEPTIDES AND USES THEREOF
US11116519B2 (en) 2017-09-26 2021-09-14 Si-Bone Inc. Systems and methods for decorticating the sacroiliac joint
EP4516267A3 (en) 2018-03-28 2025-05-21 SI-Bone, Inc. Threaded implants and methods of use across bone segments
SG11202012340SA (en) * 2018-06-11 2021-01-28 Oramed Ltd Recombinant protease inhibitor-containing compositions, methods for producing same and uses thereof
JP2022520101A (ja) 2019-02-14 2022-03-28 エスアイ－ボーン・インコーポレイテッド 脊椎の固定及び、又は融合のためのインプラント
US11369419B2 (en) 2019-02-14 2022-06-28 Si-Bone Inc. Implants for spinal fixation and or fusion
WO2021102429A1 (en) 2019-11-21 2021-05-27 Si-Bone Inc. Rod coupling assemblies for bone stabilization constructs
US11672570B2 (en) 2019-11-27 2023-06-13 Si-Bone Inc. Bone stabilizing implants and methods of placement across SI Joints
WO2021119126A1 (en) 2019-12-09 2021-06-17 Si-Bone Inc. Sacro-iliac joint stabilizing implants and methods of implantation
AU2021397743A1 (en) 2020-12-09 2023-06-22 Si-Bone Inc. Sacro-iliac joint stabilizing implants and methods of implantation
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof
US20240366731A1 (en) * 2021-08-12 2024-11-07 Celagenex Research (India) Pvt. Ltd. Oral algal oil based gastro-intestinal tract permeable peptide composition
EP4440505A4 (en) 2021-12-03 2025-11-19 Si Bone Inc INTERBODY CAGES AND SACROILIAC JOINT STABILIZATION METHODS
CN117186237A (zh) * 2022-05-29 2023-12-08 中国医学科学院药物研究所 一种含有糜蛋白酶抑制肽的胰岛素杂交肽及其应用
WO2025038769A1 (en) 2023-08-15 2025-02-20 Si-Bone Inc. Pelvic stabilization implants, methods of use and manufacture
WO2025152922A1 (zh) * 2024-01-15 2025-07-24 合肥天汇生物科技有限公司 使用分离的bbi和kti的多肽组合物及其用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
JPS6350793A (ja) 1986-08-20 1988-03-03 株式会社東芝 高速増殖炉の崩壊熱除去システム
US5034415A (en) 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
ES2045276T3 (es) 1988-07-21 1994-01-16 Hoffmann La Roche Preparacion de insulina
JPH02250823A (ja) 1989-03-24 1990-10-08 Tsumura & Co マイクロカプセル剤およびその製造方法
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
JPH06145198A (ja) * 1992-03-30 1994-05-24 Shokuhin Sangyo High Separeeshiyon Syst Gijutsu Kenkyu Kumiai 大豆トリプシンインヒビターの製造方法
US6692766B1 (en) 1994-06-15 2004-02-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Controlled release oral drug delivery system
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
IL114673A (en) 1995-07-19 2000-12-06 Hadasit Med Res Service Pharmaceutical compositions containing protein for oral administration
JPH09208485A (ja) 1996-01-31 1997-08-12 Teijin Ltd ペプチド・蛋白質性薬物の水難溶性組成物
DE69739172D1 (de) 1996-08-08 2009-01-29 Amylin Pharmaceuticals Inc Regulation gastrointestinaler beweglichkeit
JPH10330287A (ja) 1997-03-31 1998-12-15 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸からなる消化管吸収促進剤およびそれを含有する薬剤
JP2000128805A (ja) 1998-10-27 2000-05-09 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
JP2001240558A (ja) 2000-02-29 2001-09-04 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸を経粘膜吸収促進剤として含有する固形製剤。
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
KR20010069322A (ko) 2001-03-08 2001-07-25 서종수 휴대형정보단말기 또는 화상이동통신장치를 이용한전자경매방법
KR20010069433A (ko) 2001-03-22 2001-07-25 김윤완 노루궁뎅이버섯을 이용한 건강 보조 식품
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
EP1414474A4 (en) 2001-07-18 2005-06-29 Solae Llc PROTEIN BOWMAN BIRK HEMMER CONCENTRATE AND MANUFACTURING METHOD THEREFOR
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
JP4165329B2 (ja) * 2002-07-31 2008-10-15 不二製油株式会社 大豆ホエー分画物の製造法
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2006097793A2 (en) 2004-04-15 2006-09-21 Chiasma, Ltd. Compositions capable of facilitating penetration across a biological barrier
CN103223160B (zh) 2004-07-19 2015-02-18 比奥孔有限公司 胰岛素-低聚物共轭物,制剂及其用途
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
CN101242748A (zh) * 2004-11-26 2008-08-13 荷兰纽迪希亚公司 含有蛋白酶抑制剂的婴儿营养品
AU2006288703B2 (en) * 2005-09-06 2011-09-22 Oramed Pharmaceuticals, Inc. Methods and compositions for oral administration of proteins
US20070086972A1 (en) 2005-09-12 2007-04-19 Jacob Birnbaum Hair growth compositions and methods for treating hair loss or related conditions
US20070077283A1 (en) 2005-09-30 2007-04-05 Nastech Pharmaceutical Company Inc. Method of enhancing transmucosal delivery of therapeutic compounds
CN101095942B (zh) 2006-06-30 2011-11-16 北京民海生物科技有限公司 一种包含稳定剂的Exendin-4注射剂药物配方
CA3083198A1 (en) 2008-03-26 2009-10-01 Oramed Ltd. Methods and compositions for oral administration of proteins
EP2300031B1 (en) 2008-05-05 2017-09-20 Oramed Ltd. Methods and compositions for oral administration of exenatide
TWI474835B (zh) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑
JP5740689B2 (ja) 2008-08-18 2015-06-24 エンテラ バイオ エルティーディー． タンパク質の経口投与用の方法および組成物
EP2519251A4 (en) * 2009-12-30 2013-08-28 Solae Llc ISOLATED CLEANED BOWMAN BIRK PROTEASE HEMMER PROTEINS FROM A SOYA PROCESSING STREAM
ES2644962T3 (es) * 2012-01-03 2017-12-01 Oramed Ltd. Cápsulas que contiene composiciones líquidas basadas en aceite de agentes terapéuticos combinados para tratar la diabetes
EP4082530B1 (en) 2012-02-01 2024-04-10 Oramed Ltd. Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
EP2941267B1 (en) 2013-01-03 2022-11-16 Oramed Ltd. Compositions for use in treating nafld
SG11202012340SA (en) 2018-06-11 2021-01-28 Oramed Ltd Recombinant protease inhibitor-containing compositions, methods for producing same and uses thereof

Also Published As

Publication number Publication date
CN112755002A (zh) 2021-05-07
JP2020117518A (ja) 2020-08-06
US10933022B2 (en) 2021-03-02
DK4082530T3 (da) 2024-05-06
EP4082530A1 (en) 2022-11-02
US20140377344A1 (en) 2014-12-25
DK2814504T3 (da) 2022-05-02
US20240358647A1 (en) 2024-10-31
CN104244969A (zh) 2014-12-24
US20190321303A1 (en) 2019-10-24
EP2814504B1 (en) 2022-03-16
EP4082530B1 (en) 2024-04-10
CN113769074A (zh) 2021-12-10
WO2013114369A1 (en) 2013-08-08
EP2814504A4 (en) 2015-10-14
JP6567827B2 (ja) 2019-08-28
HK1200727A1 (en) 2015-08-14
US20210369626A1 (en) 2021-12-02
ES2912138T3 (es) 2022-05-24
JP7064226B2 (ja) 2022-05-10
HUE066433T2 (hu) 2024-08-28
JP2015510506A (ja) 2015-04-09
EP2814504A1 (en) 2014-12-24
US10342764B2 (en) 2019-07-09
JP2018104443A (ja) 2018-07-05

Similar Documents

Publication Publication Date Title
DK4082530T3 (da) Proteasehæmmerholdige sammensætninger, sammensætninger omfattende samme og fremgangsmåder til fremstilling og anvendelse af samme
DK3252160T3 (da) Systemer, fremgangsmåder og sammensætninger med crispr-cas-bestanddele til sekvensmanipulation
DK2739293T3 (da) Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
DK4537839T3 (da) Fremgangsmåde og sammensætninger til cellulær immunterapi
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK3027186T3 (da) Fremgangsmåde til fremstilling af sammensætninger, der omfatter hyaluronsyre og mepivacainhydrochlorid
DK3782639T3 (da) Sammensætninger og fremgangsmåder til internalisering af enzymer
DK2800565T3 (da) Carbamatforbindelser og fremgangsmåder til fremstilling og anvendelse af samme
DK2811876T4 (da) Kaffemaskine og fremgangsmåde til betjening af samme
DK2776567T3 (da) Sammensætninger og fremgangsmåder til behandling af cytomegalovirus.
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
DK2920149T3 (da) 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK2898061T3 (da) Probiotiske sammensætninger til behandlingen af fedme og fedme-relaterede tilstande
DK3628161T3 (da) Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
IL238958A0 (en) Glutamase inhibitors, compositions comprising same and uses thereof
DK2804587T3 (da) Formulering og fremgangsmåde til øgning af lægemidlers biotilgængelighed
DK3080274T3 (da) Fremgangsmåder og sammensætninger til genom-manipulation
DK2885261T3 (da) Flydende sammensætninger, der indeholder ureaseinhibitorer og glycolalkylethere
DK2914741T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til forbedring af PCR-specificitet
DK3421051T3 (da) Fremgangsmåder til glycokonjugering og sammensætninger
DK3594348T3 (da) Kort c/ebp-alpha til aktivering af rna-sammensætninger og anvendelsesfremgangsmåder
DK2970890T3 (da) Sammensætninger og fremgangsmåder til opformering og dyrkning af epitelstamceller
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK2928495T3 (da) Sammensætninger, der omfatter anti-cd38-antistoffer og lenalidomid